12 results about "Lens epithelial cell" patented technology

This invention provides an application of type I interferon signaling pathway inhibitors in the preparation of drugs for treating age-related cataracts. By inhibiting type I interferon receptors, it can precisely intervene in the aging mechanism of lens epithelial cells, block the transmission of aging signals, and directly improve lens transparency, exhibiting higher therapeutic efficacy and targeting. The use of IFNAR inhibitors can effectively reverse the aging phenotype caused by STEAP3 deficiency, restore the proliferative capacity of lens epithelial cells, thereby maintaining lens transparency, significantly reducing surgical risks, and providing patients with an early intervention opportunity, delaying the onset and progression of cataracts. IFNAR inhibitors, through precise intervention in specific signaling pathways, have more significant therapeutic effects, and due to their targeting, have fewer side effects and are safer. They can not only improve existing cataracts but also play a preventive and delaying role in the early stages of cataracts. For patients with mild cataracts, the use of type I interferon receptor inhibitors can avoid premature surgical treatment, reducing patient dependence on surgery and also reducing the costs and risks associated with surgery.

The present invention relates to retinal progenitor cells simultaneously exhibiting characteristics of retinal pigment epithelial cells, photoreceptor cells, and lens epithelial cells, and a mass production method therefor. When retinal progenitor cells are isolated and cultured using the method according to one aspect, the retinal progenitor cells can be mass-produced in a short time, and thus the method is economical. In addition, the isolated retinal progenitor cells exhibit all of the differentiation characteristics of retinal pigment epithelial cells, photoreceptor cells and lens epithelial cells. Therefore, the present invention can be effectively used in the fields of research on retinal diseases such as macular degeneration, and research and development of therapeutic agents.

The utility model relates to the field of biomedical engineering provides a kind of intraocular lens, to be able to alleviate postoperative inflammation.The utility model gets intraocular lens, including optical part, the optical part has first drug loading hole, the first drug loading hole is bottomed hole, in the optical part one surface opening, for accommodating drug.The above structure is adopted, since optical part has first drug loading hole, the first drug loading hole is bottomed hole, in the optical part one surface opening, therefore can fill relevant drug in drug loading hole, drug is released through the opening of optical part surface, so as to can reduce postoperative inflammation, inhibit lens epithelial cell migration, reduce the incidence of posterior capsule opacity.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

The invention relates to the technical field of drugs for delaying senescence of lens cells, and particularly discloses a pharmaceutical composition for delaying senescence of lens cells and application thereof, the pharmaceutical composition comprises 0.05-0.1 wt% of cycloastragenol ester derivatives, 0.1-5 wt% of a solubilizer, 1.0-10.0 wt% of a cosolvent, 0.5-2.0 wt% of an osmotic pressure regulator, 0.01-0.5 wt% of a buffer salt, 0.001-0.05 wt% of a preservative, and the balance of water for injection; wherein the cycloastragenol ester derivative is cycloastragenol-3-acetate, and the structural formula of the cycloastragenol ester derivative is shown in Cycloastragenol-3-acetate is applied to delaying senescence of lens cells, compared with a parent compound cycloastragenol, the esterified derivative has significantly enhanced fat solubility and cell membrane permeability, and under the same concentration, the ability of activating the telomerase activity of lens epithelial cells is significantly superior to that of cycloastragenol; stronger biological activity potential is shown.

The invention relates to a small molecule compound L28H15 for preventing and treating posterior cataract, which is used as a multi-target inhibitor, is mainly applied to prevention of posterior cataract caused by crystal epithelial intercellular interstitial transformation, provides a new target for clinical prevention and treatment of posterior cataract, and researches the action mechanism of the small molecule compound L28H15 for preventing and treating PCO. The action effects of different drug concentrations on the lens epithelial cells are explored; in animal experiments, in order to overcome the bottleneck of eye administration, a biodegradable PLGA material is adopted to construct a drug-loaded implant, and the purpose of long-acting and local slow release of L28H15 in eyes is achieved. In the later stage, the effectiveness and safety of the L28H15-PLGA implant in preventing PCO are comprehensively evaluated by constructing a rabbit eye model, so that a brand new candidate drug is provided for overcoming the clinical problem of PCO, and an administration approach with a great clinical transformation prospect is also researched.

A method for reducing radiation damage in a lens epithelial cell from a subject in which the subject has a proliferative disease and is undergoing radiation therapy to treat the disease. The method includes administering to the lens epithelial cell a radio¬ modulating polypeptide in an amount sufficient to reduce or repair DNA double strand breaks. The polypeptide is administered to the cell in an amount sufficient to reduce radiation damage to the lens epithelial cell.

The invention relates to the technical field of biological medicine, and provides application of a THBS1 protein inhibitor in preparation of a medicine for preventing and treating diabetic cataract, and the medicine plays a role by improving the pathological state of lens epithelial cells related to the diabetic cataract. Meanwhile, the invention further provides a medicine for preventing and treating diabetic cataract, and the medicine comprises the THBS1 protein inhibitor as an active ingredient. The application has the advantages that THBS1 is determined to be a key target for high glucose-induced lens epithelial cell apoptosis for the first time, the inhibitor of THBS1 can directly block a core link of disease progression, and compared with traditional drugs, the THBS1 has higher specificity and effectiveness, and specific accurate intervention on diabetic cataract is realized.

This provides a method for stimulating cell growth. [Solution] A method for stimulating cell growth, comprising the step of bringing cells into contact with a composition containing isolated lens epithelial cell-derived growth factor (LEDGF).

The application discloses a kind of in vitro directional induction lenticular lens organ by relying on stiffness controllable hydrogel and its construction method and application, technical scheme includes the following steps: (1) pluripotent stem cells are directionally induced and differentiated into primary ectoderm cell group;(2) prepare specific stiffness hydrogel and carry out surface cell adhesion treatment;(3) primary ectoderm cell is planted on the polyacrylamide hydrogel after washing and is induced into neural ectoderm cell group;(4) neural ectoderm cell is directionally differentiated into mature lenticular lens organ.The three-dimensional lenticular lens organ model obtained by the method has the top surface and the bottom surface of the spherical surface lenticular morphology, transparent and has capsule, lenticular lens epithelial cell, lenticular lens fiber cell and other structures, bottom surface is also completely wrapped by lenticular lens capsule.Compared with previous method, the formation of bottom surface complete capsule and spherical surface morphology is realized.

The invention provides an application of costus lactone in preparation of a medicine for preventing posterior capsular opacity. The costuslactone can be used for effectively relieving posterior capsular opacity after ECLE (extracellular lens extraction), and shows remarkable anti-inflammatory and anti-fibrosis effects in both in-vitro and in-vivo models. Mechanism research determines that matrix metalloproteinase 8 (MMP8) is a key downstream effector factor of costus lactone, and confirms that costus lactone inhibits MMP8 expression so as to block conversion from lens epithelial cells (LECs) to interstitial cells and a subsequent fibrosis process, and lays a solid foundation for developing a targeted therapy for a common operative complication of posterior cataract.